Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Sondrio, Italy Clinical Trials

A listing of Sondrio, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

The dose-escalation Part A of this study will involve patients with advanced solid malignancies refractory to standard therapy or for which no standard of care regimen currently exists. Approximately 30 evaluable patients per treatment arm (A1 or A2) will be enrolled. A3 will test viability of alternate dosing schedule for ...

Phase

0.0 miles

Learn More »

Trastuzumab Optimization Trial in Breast Cancer

This project consists of two independent, following specific eligibility criteria and different randomisation schemes studies, later on called maintenance study and 2nd line study. All patients enrolled in the maintenance study, after disease progression should be screened to enter the 2nd line study. Maintenance study: Open-label, randomised, phase III, multicenter, ...

Phase

0.0 miles

Learn More »

Tarceva Italian Lung Optimization tRial

Erlotinib is registered in all patients affected with NSCLC in second and subsequent lines with a small benefit on Overall Survival. Recent evidence suggest that patients with EGFR mutations have a clear benefit when they are treated with EGFR tyrosine kinase inhibitors, while the role of these drugs in wild-type ...

Phase

0.0 miles

Learn More »

Does Timing of VT Ablation Affect Prognosis in Patients With an Implantable Cardioverter-defibrillator?

Enrolled patients will remain in a first phase of the study until the first appropriate ICD shock will be delivered. The objective of this first stage is to assess whether the burden of untreated non sustained VTs or episodes treated with anti-tachycardia pacing is predictive of appropriate ICD shocks. The ...

Phase N/A

0.0 miles

Learn More »

Overcoming Endocrine Resistance in Metastatic Breast Cancer

In presence of ER hypersensitivity even a small amount of ER may be sufficient for sustained growth signalling. On the other hand, ER disruption operated by fulvestrant is not complete, particularly in the initial phase of treatment. From phase III trials, indeed, The invertigators know that with the standard 250mg ...

Phase

0.0 miles

Learn More »

Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer

Although the incidence of the adenocarcinoma of the stomach is slowly decreasing, gastric cancer represents the second worldwide cause of cancer death after lung cancer. In patients with advanced disease, chemotherapy improves survival and quality of life. Combinations of two or three drugs including a platin derivative (cisplatin or oxaliplatin), ...

Phase

0.0 miles

Learn More »

A Study to Evaluate Safety Efficacy Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 an Anti-PD-1 Monoclonal Antibody in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations

This open-label (all people know identity of intervention) and multicenter (when more than one hospital or medical school team work on a medical research study) study of erdafitinib plus JNJ-63723283 in participants with advanced urothelial cancer with selected fibroblast growth factor receptor (FGFR) gene alterations who have progressed on or ...

Phase

0.0 miles

Learn More »

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

The co-primary objectives are to assess investigator-assess, and blinded independent centrally-reviewed progression-free survival .

Phase

0.0 miles

Learn More »

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Patients eligible for the study will receive 6 courses (q 28 days) of the DEVEC combination, according to the following schedule: DE: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 it is reduced to ...

Phase

0.0 miles

Learn More »